Senses Disorder TRIZ Cases

Cysteamine ophthalmic composition reduces dysfunctional tear syndrome symptoms through targeted enzyme inhibition.

Co-injecting transgene peptides with AAV vectors modulates immune responses, preventing secondary vision loss from anti-transgene T-cell activation.

Aromatic heterocyclic compounds inhibit ALK5 to block Smad2/3 phosphorylation, correcting abnormal TGF-β signaling in fibrosis and cancer.

A pharmaceutical composition combines a cysteinyl leukotriene receptor antagonist with Ginkgo biloba extract to protect inner ear tissues.

Organic carboxylic acids form stable supersaturated bilastine solutions that overcome low water solubility limits for reliable antihistamine delivery.

Fusion proteins combine TAT and MTS domains to transport functional enzymes into mitochondria, bypassing blood-brain barrier limitations.

Isolated antibodies bind homodimeric IL-17A and heterodimeric IL-17AF to inhibit pro-inflammatory cytokine activity.

Sintokamide compounds inhibit ligand-independent androgen receptor transcriptional activity, resolving resistance in castration-resistant prostate cancer.

N-terminal mini-PEG and acylation modifications extend peptide half-life, enabling central nervous system access to treat migraines.

Three-dimensional allogeneic retinal tissue aggregates suppress immune activation, preventing graft rejection without systemic immunosuppressive agents.

Administering high-dose atorvastatin regresses drusen and prevents retinal pigment epithelium atrophy in dry age-related macular degeneration patients.

A bispecific molecule binds TLR9 and CD32 to activate allergen-specific Th1 cells.

DNA-directed RNA interference agents silence target genes in retinal tissue, avoiding interferon activation and extending treatment duration.

A novel RdCVF2v polypeptide isoform rescues neurons and promotes viability in retinal tissue.

Segmented RGD peptides deliver therapeutic agents directly to tumors via integrin binding, sparing normal tissue from systemic toxicity.

Cationic lipid compositions encapsulate mRNA via electrostatic interactions, reducing toxic side effects from high agent concentrations.

Specific pyridine-2-amine structures block SOC channel proteins, reducing pathological cytokine release in inflammatory disorders.

Antisense oligonucleotides bind to VEGF polynucleotides via sequence-specific hybridization.

Fructosamine-3-kinase enzymatically disrupts glycated lens proteins to restore transparency, replacing invasive surgery and reducing infection risk.

Single domain antibodies block CD40L without triggering platelet aggregation, resolving thromboembolic risks in autoimmune treatments.

Segmenting the 46 kDa PEDF protein into smaller bioactive fragments resolves the trade-off between therapeutic efficacy and delivery complexity.

Isoacteoside reduces Aβ1-40 accumulation and inhibits Aβ1-42 oligomerization, addressing inadequate current treatments for Alzheimer's disease.

Tissue-specific promoters in enhanced expression vectors resolve the contradiction between high expression efficiency and reliable suppression specificity.

Covalent GLP-1 gastrin peptide conjugates address limited therapeutic efficacy of individual peptides by merging agonist functions into a single molecule.

Engineered monoclonal antibodies with optimized binding kinetics rapidly neutralize lysophosphatidic acid, replacing slow semi-quantitative detection methods.

Oligonucleotide kits detect MMP25 and BATF alleles to guide anti-VEGF antibody treatment selection, resolving variable patient responsiveness in wet AMD care.

A herbal composition comprising fermented Alpinia galanga and Phyllanthus emblica extracts improves visual acuity.

Injectable swellable microspheres deliver therapeutic agents directly to tumor sites via active embolization.

HPMC and CMC sodium matrix maintains therapeutic plasma levels for 8 to 14 hours, reducing dosing frequency.

Phospholipid gel matrices encapsulate aptamers to maintain steady blood levels and reduce side effects from immediate-release fluctuations.

Positively charged liposome vesicles overcome corneal and scleral barriers to deliver lutein and zeaxanthin via iontophoresis.

Gentle mixing of cyclosporine nanoemulsion phases avoids high-temperature instability while ensuring uniform particle distribution.

A pharmaceutical composition containing astaxanthin, piperine, and coenzyme Q10 promotes retinal functional recovery.

KAI1 polypeptides target pericytes to suppress angiogenesis, preserving vessel integrity and reducing bleeding risks associated with anti-VEGF therapies.

A fixed-dose pharmaceutical composition combines anti-PD-1 and anti-CTLA-4 antibodies in a single formulation.

Segmented biodegradable microparticles enable sustained release of water-soluble biotherapeutics, reducing frequent intravitreous injections.

Combining PI3K delta inhibitors with PDE4 blockers reduces side effects while enhancing treatment efficacy for autoimmune diseases.

Combining HIF-1α and HIF-2α siRNAs resolves insufficient VEGF suppression by single isoform inhibitors, enhancing therapeutic reliability for retinal diseases.

Integrin ligand fused to anti-angiogenesis polypeptide resolves poor target specificity and high dosage requirements.

Stabilized soluble alpha-synuclein oligomers bind target proteins, enabling early detection and treatment before insoluble aggregates form.